Runt-related gene 2 is involved in the inhibition of matrix metalloproteinase-13 expression by roxithromycin in human gingival epithelial cell cultures.
OBJECTIVE
Matrix metalloproteinase (MMP)-13 has wide substrate specificity compared with other MMPs and appears to be involved in periodontitis. Previously, we reported that roxithromycin (RXM) inhibits vascular endothelial growth factor expression induced by tumour necrosis factor-alpha in human periodontal ligament cells, but little is known about the effect of RXM on MMP-13 expression in human gingival epithelial cells. We therefore examined the effect of RXM on MMP-13 mRNA expression and production in cultured human gingival epithelial cells.


METHODS
Human epithelial cell lines (Ca9-22, TU4, SCCTF and HSC-3) were plated in tissue culture dishes. Then, the culture supernatants and sediments were collected and the production of MMP-13 was analysed using enzyme-linked immunosorbent assay; the expression of MMP-13 mRNA and runt-related gene 2 mRNA was assessed using reverse transcriptase-polymerase chain reaction (RT-PCR) and real-time RT-PCR. We also studied the effect of Runx2 short interfering RNA (siRNA) on the induction of MMP-13.


RESULTS
Roxithromycin downregulated the induction of MMP-13 in Ca9-22 cells. Roxithromycin suppressed the expression of MMP-13 mRNA not only in Ca9-22 cells, but also in other human epithelial cell lines. Roxithromycin strongly inhibited the expression of Runx2 mRNA. Furthermore, Runx2 siRNA inhibited the induction of MMP-13 in Ca9-22 cells.


CONCLUSIONS
These results indicate that RXM suppresses MMP-13 via the downregulation of Runx2 in human gingival epithelial cell cultures.
Tabuchi
Seiko
S
Department of Restorative Dentistry and Endodontology, Kagoshima University, Kagoshima, Japan.
Sakuta
Tetsuya
T
Oyama
Tohru
T
Tokuda
Masayuki
M
Tatsuyama
Syouko
S
Kajihara
Takehiro
T
Nagaoka
Shigetaka
S
Beppu
Mahiro
M
Sugihara
Kazumasa
K
Ikebe
Tetsuro
T
Shirasuna
Kanemitsu
K
Torii
Mitsuo
M
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D045744:Cell Line, Tumor; D050659:Core Binding Factor Alpha 1 Subunit / Q000096:biosynthesis / Q000235:genetics* / Q000502:physiology; D015536:Down-Regulation; D004790:Enzyme Induction / Q000187:drug effects*; D004847:Epithelial Cells / Q000201:enzymology; D005881:Gingiva / Q000166:cytology / Q000201:enzymology*; D006801:Humans; D053509:Matrix Metalloproteinase 13 / Q000096:biosynthesis / Q000235:genetics; D061965:Matrix Metalloproteinase Inhibitors; D034622:RNA Interference; D012333:RNA, Messenger / Q000096:biosynthesis; D034741:RNA, Small Interfering / Q000096:biosynthesis / Q000502:physiology; D015575:Roxithromycin / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D050659:Core Binding Factor Alpha 1 Subunit; D061965:Matrix Metalloproteinase Inhibitors; D012333:RNA, Messenger; D034741:RNA, Small Interfering; C493709:RUNX2 protein, human; D015575:Roxithromycin; D053509:Matrix Metalloproteinase 13